INFLUENCE OF APO-E POLYMORPHISM ON THE RESPONSE TO SIMVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

被引：0
|
作者：
DEKNIJFF, P
STALENHOEF, AFH
MOL, MJTM
LEUVEN, JAG
SMIT, J
ERKELENS, DW
SCHOUTEN, J
FRANTS, RR
HAVEKES, LM
机构：
[1] TNO, GAUBIUS INST, POB 612, 2300 AP LEIDEN, NETHERLANDS
[2] UNIV HOSP NIJMEGEN, DEPT MED, DIV GEN INTERNAL MED, NIJMEGEN, NETHERLANDS
[3] STATE UNIV UTRECHT HOSP, DEPT ENDOCRINOL, 3511 GV UTRECHT, NETHERLANDS
[4] FREE UNIV AMSTERDAM HOSP, DIV INTERNAL MED, 1081 HV AMSTERDAM, NETHERLANDS
[5] LEIDEN STATE UNIV, DEPT HUMAN GENET, 2312 AV LEIDEN, NETHERLANDS
来源：
ATHEROSCLEROSIS | 1990年 / 83卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：89 / 97
页数：9
相关论文
共 50 条
  • [1] Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia
    Vohl, MC
    Szots, F
    Lelièvre, M
    Lupien, PJ
    Bergeron, J
    Gagné, C
    Couture, P
    ATHEROSCLEROSIS, 2002, 160 (02) : 361 - 368
  • [2] THE RESPONSE TO LOVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS MODULATED BY APOLIPOPROTEIN-E POLYMORPHISM
    CARMENA, R
    ROEDERER, G
    MAILLOUX, H
    LUSSIERCACAN, S
    DAVIGNON, J
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (07): : 895 - 901
  • [3] Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin
    Bo, M
    Nicolello, MT
    Fiandra, U
    Mercadante, G
    Piliego, T
    Fabris, F
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2001, 11 (01) : 17 - 24
  • [4] HYPERTRIGLYCERIDEMIA AND APO-E POLYMORPHISM
    BRENNINKMEIJER, BJ
    STUYT, PM
    DEMACKER, PN
    STALENHOEF, AF
    VANTLAAR, A
    ARTERIOSCLEROSIS, 1986, 6 (05): : A546 - A546
  • [5] A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
    Kitatani, M
    Koizumi, J
    Inazu, A
    Kajinami, K
    Mabuchi, H
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1996, 57 (01): : 62 - 71
  • [6] FREQUENCY AND ROLE OF APO-E PHENOTYPE IN FAMILIAL HYPERCHOLESTEROLEMIA AND NONFAMILIAL HYPERLIPIDEMIA IN THE JAPANESE
    KITAHARA, M
    SHINOMIYA, M
    SHIRAI, K
    SAITO, Y
    YOSHIDA, S
    ATHEROSCLEROSIS, 1990, 82 (03) : 197 - 204
  • [7] THE INFLUENCE OF APOLIPOPROTEIN-E PHENOTYPE ON THE RESPONSE TO LOVASTATIN THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    OMALLEY, JP
    ILLINGWORTH, DR
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (02): : 150 - 154
  • [8] VLDL APO-B-100 AND APO-E KINETICS IN FAMILIAL HYPERCHOLESTEROLEMIA USING STABLE ISOTOPES
    SCHAEFER, JR
    GREGG, RE
    FAIRWELL, T
    ZECH, LA
    RADER, DJ
    KINDT, MR
    BREWER, HB
    ARTERIOSCLEROSIS, 1989, 9 (05): : A713 - A713
  • [9] COMBINED TREATMENT WITH SIMVASTATIN AND ACIPIMOX IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH ELEVATED LIPOPROTEIN(A)
    MULS, E
    BEX, M
    COBBAERT, C
    VANSANT, G
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 1994, 4 (02) : 78 - 82
  • [10] APO-E POLYMORPHISM AND PLASMA-CHOLESTEROL RESPONSE TO PROBUCOL
    NESTRUCK, AC
    SING, CF
    BOUTHILLIER, D
    DAVIGNON, J
    ARTERIOSCLEROSIS, 1985, 5 (05): : A505 - A505
12345